A5028554037- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Platelet Disorders and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Blood groups and transfusion
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Complement system in diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Protein Degradation and Inhibitors
- T-cell and Retrovirus Studies
- Neuroendocrine Tumor Research Advances
- Cystic Fibrosis Research Advances
- Multiple and Secondary Primary Cancers
- Renal Diseases and Glomerulopathies
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Cardiac tumors and thrombi
- Blood transfusion and management
- HER2/EGFR in Cancer Research
Geelong Hospital
2018-2025
Deakin University
2021-2025
Barwon Health
2022-2024
St John of God Geelong Hospital
2023
St John of God Hospital
2023
Monash Health
2015-2019
The Royal Melbourne Hospital
2014-2019
Monash University
2019
Monash Medical Centre
2017
Certain patients with antibody-mediated autoimmune disease exhibit poor responses to conventional immunosuppression, including B-cell depletion rituximab. Proteasome inhibitors such as bortezomib demonstrate pleiotropic immunomodulatory effects, direct toxicity antibody-producing cells. Here, we report preliminary evidence for the efficacy of salvage therapy refractory hematological disease. Thirteen treatment episodes in 10 phenomena (autoimmune hemolytic anemia [AIHA; n = 8], acquired...
Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) chronic phase myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, although the incidence of these events is well described, response to therapy dose modifications on not been comprehensively characterized real-world setting. We retrospectively reviewed dasatinib adverse 212 patients at 17...
Abstract Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial many novel therapies RR‐DLBCL have not been replicated routine care cohorts, as patient populations are heterogeneous eligibility increasingly restrictive. We evaluated outcomes from pola ± patients enrolled a compassionate access...
Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses chronic myeloid leukemia phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk vascular AEs (VAEs) other TKIs, although natural history these events response to dose modifications or cessation has not...
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of BCR::ABL1 oncogene. Real-world clinical outcomes patients with tyrosine kinase (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on Managed Access Programme for asciminib showed higher molecular responses those intolerance versus resistance ± to their last TKI. There remains need improve CML who have multiple TKIs, especially ponatinib-pretreated cohort.
Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of have refractory disease or experience adverse effects. Studies demonstrated busulfan (Bu) to be an active agent, data on its role second-line later are minimal. To evaluate efficacy and safety in this context, we undertook multicenter audit Ph-neg MPN who had received Bu Hu intolerance failure. Of 51...
Introduction: BTK inhibitors have been shown to be highly active in WM, particularly WM harboring a MYD88 mutation (MYD88MUT). BGB-3111 is potent, specific, and irreversible inhibitor. In primary patient (pt) samples, demonstrated profound inhibition with minimal of off-target kinases such as EGFR, ITK, JAK3, HER2, TEC. phase 1 testing, high plasma concentrations were safely achieved, resulting complete, sustained blood lymph nodes. Methods: This was an open-label, multicenter, dose-finding...
TPS7092 Background: The most common therapy FL pts receive remains chemotherapy which yields high efficacy but also significant toxicity.(Marcus 2017, Rummel 2013). are largely aged over 65 and may require treatment multiple times their disease course thus novel regimens enhance minimise toxicity highly desirable. patient (pt) outcomes influenced by tumor microenvironment composition manipulation with immunotherapy. Ikaros Aiolos, key cell development homeostasis transcription factors...
Abstract Background Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain be determined. Methods We performed a retrospective study immunocompetent, adult patients histologically confirmed diffuse large B‐cell the CNS (PCNSL). 190/204 (93%) (median age: 65) received one five high‐dose methotrexate (HD‐MTX) containing chemotherapy regimens: MPV/Ara‐C (HD‐MTX, procarbazine, and...
Population-based studies have demonstrated a high risk of second cancers, especially the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) primary malignancies (SPM) in Australian relapsed/refractory CLL treated at least two lines therapy, including ibrutinib. From December 2014 to November 2017, 156 were identified from 13 sites enrolled Australasian Lymphoma and Related Diseases Registry, 111 had follow-up data on rates SPM....
Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on histological continuum between 'lowgrade' (Grade 1, 2 and 3A FL) diffuse large B-cell (DLBCL) appearing to share features with each. Clinical characteristics outcomes are poorly understood due lack of adequate representation in prospective trials large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, two comparator groups; G3AFL (n=302) DLBCL (n=548). Composite histology or low-grade occurred...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: More effective treatments are needed for patients (pts) with high-risk (HR) DLBCL, where response at 3-years is ~50%. Intensification of R-CHOP chemotherapy has not improved outcomes. Furthermore, pts HR disease frequently excluded from trials due to burden and the need rapid treatment initiation, an independent predictor poor outcome (Maurer, JCO 2018). Glofitamab a CD20/CD3 bispecific antibody achieving 39% complete...
Summary Mantle cell lymphoma (MCL) is a B‐cell non‐Hodgkin characterised by heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about optimal therapy sequencing. Novel agents, such as chimeric antigen receptor T‐cell therapies and bispecific antibodies, show promise in relapsed MCL, but are reserved for later treatment lines, which may underserve patients with aggressive...
The role of cytarabine-based induction and autologous stem cell transplantation (ASCT) in front-line treatment younger patients with mantle lymphoma (MCL) is well established, however the utility intensive approaches older remains unclear. This retrospective study compared first line outcomes aged 60 years or more, treated at six tertiary centres between 2000-2015. 70 included had a median age 69 (60-91) most (94%) demonstrated advanced stage disease. Treatment regimens included: R-CHOP-like...
e19584 Background: This open-label, multicenter, phase 1b study evaluated the safety and efficacy of blinatumomab pembrolizumab combination therapy in patients (pts) with R/R DLBCL (NCT03340766). Methods: Key inclusion criteria included adults ECOG performance status ≤2 life expectancy ≥12 weeks. In cycle 1, pts received a continuous intravenous (cIV) infusion followed by step dosing to target dose (TD; Table). After 28-day treatment-free interval, cIV was administered for 28 days 2 same...
Introduction: BGB-3111 is a potent, highly specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor, with greater selectivity for BTK vs other TEC- EGFR-family kinases favorable pharmacokinetic pharmacodynamic properties. was shown to achieve complete, continuous occupancy in peripheral blood mononuclear cells lymph nodes associated durable clinical responses patients (pts) CLL/SLL Waldenström macroglobulinemia. Here, updated preliminary safety activity data relapsed/refractory...
Background: Improved treatments are needed for patients (pts) with high-risk (HR) DLBCL. Intensification of R-CHOP has not improved outcomes. Furthermore, pts HR disease frequently excluded from trials due the need rapid treatment initiation, an independent predictor poor outcome. Glofitamab (glo) is a CD20/CD3 bispecific antibody achieving 39% complete remission (CR) rate R/R DLBCL (Dickinson, NEJM 2023). We present interim analysis ongoing investigator-initiated, parallel-arm, phase I/II...
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic management algorithms have occurred within last decade. The availability of next-generation sequencing measurable residual disease assessment by flow cytometry allow for advanced prognostication response assessments. Novel therapies, including inhibitors Bruton's tyrosine kinase (BTKi) B-cell lymphoma 2 (BCL2) inhibitors, transformed...
Abstract Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse common. Several induction conditioning regimens are used in transplant‐eligible patients, the optimal approach remains unknown. We performed international, retrospective study patients to assess impact chemoimmunotherapy on clinical outcomes. identified 228 meeting inclusion criteria. Baseline characteristics were similar among groups except for some...
Abstract Current guidelines for treating vaccine-induced immune thrombotic thrombocytopenia (VITT) recommend non-heparin anticoagulants and intravenous immunoglobulin (IVIg). However, the efficacy of these treatments remains uncertain due to a lack comparative clinical trials or animal studies. A recent study proposed danaparoid heparin as potential VITT therapies their ability disrupt IgG-PF4 binding. Here, we examined effects various (including unfractionated (UF) heparin, danaparoid,...